Clinical Trials Sponsored by Dynacure

Total 9 results

Dynacure

Withdrawn

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies (DyNaMic)

Centronuclear Myopathy

Germany, France
Dynacure

Terminated

Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies (Unite-CNM)

Centronuclear Myopathy

France, Netherlands, United Kingdom, Belgium, Denmark, Germany
Dynacure

Withdrawn

Natural History Study of Patients With Centronuclear Myopathies (NatHis-CNM)

Centronuclear Myopathy
Institut de Myologie, France
Dynacure

Completed

Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies (NatHis-CNM)

Centronuclear Myopathy

France, Belgium, Germany, Italy, Spain
DynamiCure Biotechnology

Terminated

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
University of British Columbia
Genome British Columbia; Genome Canada; Dynacare Laboratories, Inc.

Recruiting

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Adverse Drug Reaction (ADR)

Canada
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19

3

Subscribe